4.50
+0.31(+7.40%)
Currency In USD
| Previous Close | 4.19 |
| Open | 4.05 |
| Day High | 4.54 |
| Day Low | 3.95 |
| 52-Week High | 37.5 |
| 52-Week Low | 2.84 |
| Volume | 37,430 |
| Average Volume | 54,167 |
| Market Cap | 7.99M |
| PE | -0.2 |
| EPS | -22.9 |
| Moving Average 50 Days | 5.59 |
| Moving Average 200 Days | 7.45 |
| Change | 0.31 |
If you invested $1000 in Lyra Therapeutics, Inc. (LYRA) since IPO date, it would be worth $4.85 as of December 05, 2025 at a share price of $4.5. Whereas If you bought $1000 worth of Lyra Therapeutics, Inc. (LYRA) shares 3 years ago, it would be worth $26.55 as of December 05, 2025 at a share price of $4.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
GlobeNewswire Inc.
Oct 06, 2025 11:00 AM GMT
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Jun 27, 2025 12:00 PM GMT
Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement WarrantsWATERTOWN, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
GlobeNewswire Inc.
Jun 02, 2025 11:00 AM GMT
ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078)ENLIGHTEN 2 trial also showed statistically significant improve